Health

Lilly Ups Guidance on Weight Loss, Obesity Drugs’ Strength

Provide news feedback or report an error

Confidential tip?

Send a tip to our reporters

Site feedback:

Take our Survey

By Madison Muller

October 30, 2025 at 10:54 AM UTC

Updated on

October 30, 2025 at 3:52 PM UTC

Eli Lilly & Co. raised its full-year guidance as revenue from its blockbuster weight loss and diabetes drugs beat expectations in the third quarter and it began solidifying its lead over its biggest rival.

The company’s shares rose 3% at 9:33 a.m. in New York on Thursday, after gaining 5.4% this year through Wednesday’s close.